Kymera Therapeutics, Inc. (KYMR) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-99.8%

$0.20

vs $127.66 price

Levered DCF

-$0.05

After debt service

Piotroski score

4 / 9

Average

Altman Z-score

41.46

Safe zone

Rating

C-

Overall 1 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-21.09×	-13.5×	-10.1×	-8.7×	-30.38×	-62.63×	-35.76×	-69.29×
P/B	4.16×	3.61×	3.76×	2.75×	6.63×	9.73×	-19.91×	-43.01×
P/S	167.51×	64.14×	18.91×	28.75×	41.83×	81.17×	504.79×	0×
EV / EBITDA	-20.76×	-13.81×	-10.2×	-8.54×	-30.9×	-62.9×	-35.32×	-67.8×
Gross margin	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	71.9%	0.0%
Operating margin	-891.3%	-555.8%	-210.6%	-344.4%	-138.0%	-136.1%	-1438.5%	0.0%
Net margin	-794.4%	-475.6%	-187.0%	-330.6%	-137.6%	-134.0%	-1407.4%	0.0%
Current ratio	10.47×	7.53×	4.73×	5.88×	4.88×	2.73×	2.69×	8.92×
Debt / equity	0.05×	0.11×	0.21×	0.04×	0.04×	0.06×	-0.28×	-0.02×
Interest coverage	-1,403.21×	-1,050.74×	-844.54×	-916.23×	-574.46×	-402.64×	-917.5×	-1,340.69×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-19.7%	-26.8%	-37.2%	-31.6%	-21.8%	-16.1%	55.5%	62.3%
Return on invested capital	-20.9%	-28.3%	-33.3%	-30.1%	-19.4%	-12.2%	-49.4%	-53.8%
Return on assets	-17.9%	-22.9%	-25.5%	-25.7%	-16.5%	-9.4%	-35.4%	-48.5%
Free cash flow yield	-3.6%	-6.9%	-9.2%	-11.6%	-4.3%	2.9%	1.2%	-1.3%
Earnings yield	-4.7%	-7.4%	-9.9%	-11.5%	-3.3%	-1.7%	-2.8%	-1.4%
Enterprise value	$6.3B	$3B	$1.5B	$1.3B	$3B	$2.7B	$1.4B	$1.4B
Net debt / EBITDA	0.91×	0.15×	0.18×	0.34×	0.31×	0.3×	1.36×	1.91×
Cash conversion cycle (days)	0	7	87	20	1	15	-1,449	-3,661